RxKinetix recently completed a phase II trial of RK-0202 in patients with head and neck cancer. The trial successfully demonstrated the drug’s efficacy, with patients receiving RK-0202 having statistically lower incidences of oral mucositis versus placebo.
In addition, significantly fewer patients on RK-0202 required the use of an external feeding tube compared with placebo. Patients receiving RK-0202 also had lower incidence of adverse events such as weight loss, anorexia, dry mouth, nausea and dehydration.
“I am happy with the results of the phase II trial for RK-0202.” said Dr Stephen Sonis, professor of the Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine. “I continue to be encouraged with the efficacy of RK-0202 and I am hopeful it will be an important drug for the treatment of oral mucositis.”